Cargando…

Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects

Bromocriptine-QR is a sympatholytic dopamine D2 agonist for the treatment of type 2 diabetes that has demonstrated rapid (within 1 year) substantial reductions in adverse cardiovascular events in this population by as yet incompletely delineated mechanisms. However, a chronic state of elevated sympa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cincotta, Anthony H., Cersosimo, Eugenio, Alatrach, Mariam, Ezrokhi, Michael, Agyin, Christina, Adams, John, Chilton, Robert, Triplitt, Curtis, Chamarthi, Bindu, Cominos, Nicholas, DeFronzo, Ralph A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407769/ https://www.ncbi.nlm.nih.gov/pubmed/36012132 http://dx.doi.org/10.3390/ijms23168851

Ejemplares similares

Glucose lowering and vascular protective effects of cycloset added to GLP‐1 receptor agonists in patients with type 2 diabetes
por: Alatrach, Mariam, et al.
Publicado: (2018)

Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus
por: Chamarthi, Bindu, et al.
Publicado: (2015)

Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus
por: Chamarthi, Bindu, et al.
Publicado: (2019)

Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
por: Alatrach, Mariam, et al.
Publicado: (2020)

Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
por: Gaziano, J. Michael, et al.
Publicado: (2012)

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study
por: Roe, Erin D., et al.
Publicado: (2015)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes
por: Ramteke, Karuna Balwant, et al.
Publicado: (2011)

Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet
por: Ezrokhi, Michael, et al.
Publicado: (2021)

Brain Dopamine–Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects
por: Cincotta, Anthony H.
Publicado: (2023)

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
Publicado: (2015)

Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes
por: Gaziano, J. Michael, et al.
Publicado: (2010)

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study
por: Solis-Herrera, Carolina, et al.
Publicado: (2013)

Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA(1c), in Patients With Type 2 Diabetes
por: Ali, Ali Muhammed, et al.
Publicado: (2020)

Experimental dopaminergic neuron lesion at the area of the biological clock pacemaker, suprachiasmatic nuclei (SCN) induces metabolic syndrome in rats
por: Luo, Shuqin, et al.
Publicado: (2021)

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
por: Al Jobori, Hussein, et al.
Publicado: (2018)

Pro-thrombotic condition in a woman with peripartum cardiomyopathy treated with bromocriptine and an Impella LP 2.5 heart pump
por: Schroeter, Marco R., et al.
Publicado: (2012)

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
por: DeFronzo, Ralph A., et al.
Publicado: (2010)

Increased sympathetic tone contributes to cardiovascular dysfunction in sepsis
por: Favero, Ana Maria, et al.
Publicado: (2013)

Sustained hypoxia in mice increases parasympathetic but not sympathetic tone
por: Souza, Juliana R., et al.
Publicado: (2022)

Test_QR
por: test, uni
Publicado: (2015)

Short-Term Exercise Training Improves Insulin Sensitivity but Does Not Inhibit Inflammatory Pathways in Immune Cells from Insulin-Resistant Subjects
por: Reyna, Sara M., et al.
Publicado: (2013)

Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
por: Missale, C., et al.
Publicado: (1995)

Sympathetic tone dictates the impact of lipolysis on FABP4 secretion
por: Prentice, Kacey J., et al.
Publicado: (2023)

Prediction of response to bromocriptine in acromegaly.
por: Atkinson, A. B., et al.
Publicado: (1978)

Repurposing of Bromocriptine for Cancer Therapy
por: Seo, Ean-Jeong, et al.
Publicado: (2018)

Central Hyperthermia Treated with Bromocriptine
por: Natteru, P., et al.
Publicado: (2017)

QR codes in neurosurgery
por: Kubben, Pieter L
Publicado: (2011)

Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Impaired left ventricular diastolic function in T2DM patients is closely related to glycemic control
por: Clarke, Geoffrey D., et al.
Publicado: (2018)

Dynamic resistance training decreases sympathetic tone in hypertensive ovariectomized rats
por: Shimojo, G.L., et al.
Publicado: (2015)

Sympathetic Tone Induced by High Acoustic Tempo Requires Fast Respiration
por: Watanabe, Ken, et al.
Publicado: (2015)

Evidence for the emergence of leg sympathetic vasoconstrictor tone with age in healthy women
por: Moore, David J., et al.
Publicado: (2015)

Hypertension in Obese Black Women is Not Caused by Increased Sympathetic Vascular Tone
por: Marinos, Alejandro, et al.
Publicado: (2017)

Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats
por: Ezrokhi, Michael, et al.
Publicado: (2014)

Erratum: Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats
por: Ezrokhi, Michael, et al.
Publicado: (2015)

Bromocriptine, a clinical and pharmacological review /
por: Thorner, Michael O.
Publicado: (1980)

Bromocriptine in type 2 diabetes mellitus
por: Shivaprasad, C., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7lpuai9dcl6gkqvem4gd4mo3id